About NF-kappa-B inhibitor-like protein 1
NF-kappa-B inhibitor-like protein 1 (NFKBIL1) is a protein
from Homo sapiens identified by UniProt accession
Q9UBC1, 381 residues long.
MolForge cross-references it against 0 known binders and
73 disease associations.
Target properties
| Protein name | NF-kappa-B inhibitor-like protein 1 |
| UniProt accession | Q9UBC1 |
| Gene | NFKBIL1 |
| Organism | Homo sapiens |
| Length | 381 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (73)
Diseases linked to this target (Open Targets).
- rheumatoid arthritis · score 0.42
- age at menopause · score 0.17
- childhood onset asthma · score 0.14
- mortality · score 0.08
- Sepsis · score 0.08
- natural cytotoxicity triggering receptor 3 measurement · score 0.07
- MHC class I polypeptide-related sequence B measurement · score 0.06
- Takayasu arteritis · score 0.06
- urate measurement · score 0.05
- allergic disease · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UBC1-F1 | alphafold | PREDICTED | 77.16 | — |
Amino-acid sequence (381 residues)
MSNPSPQVPE EEASTSVCRP KSSMASTSRR QRRERRFRRY LSAGRLVRAQ ALLQRHPGLD VDAGQPPPLH RACARHDAPA LCLLLRLGAD PAHQDRHGDT ALHAAARQGP DAYTDFFLPL LSRCPSAMGI KNKDGETPGQ ILGWGPPWDS AEEEEEDDAS KEREWRQKLQ GELEDEWQEV MGRFEGDASH ETQEPESFSA WSDRLAREHA QKCQQQQREA EGSRRPPRAE GSSQSWRQQE EEQRLFRERA RAKEEELRES RARRAQEALG DREPKPTRAG PREEHPRGAG RGSLWRFGDV PWPCPGGGDP EAMAAALVAR GPPLEEQGAL RRYLRVQQVR WHPDRFLQRF RSQIETWELG RVMGAVTALS QALNRHAEAL K
Explore NF-kappa-B inhibitor-like protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets